The questionable use of unequal allocation in confirmatory trials

Neurology

Volumn 82, Issue 1, 2014, Pages 77-79

  Hey, Spencer Phillips ^a   Kimmelman, Jonathan ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; EQUIPOISE; INTERNAL VALIDITY; MEDICAL ETHICS; MEDICAL INFORMATION; MEDICAL RESEARCH; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZATION;

EID: 84892169662     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000438226.10353.1c     Document Type: Article

References (19)

1. Broderick JP, Palesch YY, Demchuck AM. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013;368:893-903.
2. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009;66:460-471.
3. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14-24. (Pubitemid 46214240)
4. Le Witt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial. Ann Neurol 2008; 63:295-302. (Pubitemid 351499859)
5. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006;60:22-31.
6. Dumville JC, Hahn S, Miles JN, Torgerson DJ. The use of unequal randomisation ratios in clinical trials: a review. Contemp Clin Trials 2006;27:1-12. (Pubitemid 41758434)
7. Kim SY, Wilson RM, Frank SA, et al. An approach to evaluating the therapeutic misconception. IRB 2009;31: 7-14.
8. Kimmelman J. The therapeutic misconception at 25: treatment, research, and confusion. Hastings Cent Rep 2007; 37:36-42.
9. Karlawish J, Cary MS, Rubright J, Tenhave T. How redesigning AD clinical trials might increase study partners' willingness to participate. Neurology 2008; 71:1883-1888.
10. Grill JD, Karlawish J. Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. Alzheimers Res Ther 2010;2:34.
11. Vozdolska R, Sano M, Aisen P, Edland SD. The net effect of alternative allocation ratios on recruitment time and trial cost. Clin Trials 2009;6:126-132.
12. Meinert CL. Clinical Trials Design, Conduct, and Analysis. New York: Oxford University Press; 1986.
13. Avins AL. Can unequal be more fair? Ethics, subject allocation, and randomised clinical trials. J Med Ethics 1998; 24:401-408. (Pubitemid 28556469)
14. Roy J. Randomized treatment-belief trials. Contemp Clin Trials 2012;33:172-177.
15. Lidstone SC, Schulzer M, Dinelle K, et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry 2010;67:857-865.
16. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009;19:34-40.
17. Kimmelman J. A theoretical framework for early human studies: uncertainty, intervention ensembles, and boundaries. Trials 2012;13:173.
18. Schoenfeld DA, Cudkowicz M. Design of phase II ALS clinical trials. Amyotroph Lateral Scler 2008;9:16-23. (Pubitemid 351260368)
19. Cudkowicz ME, Katz J, Moore DH, et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11:259-265.